stockportfolio.pro
ROIV vs UTHR: Which Stock Is the Better Buy?
Roivant Sciences Ltd. and United Therapeutics Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ROIV vs UTHR, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Roivant Sciences Ltd. (ROIV) | United Therapeutics Corporation (UTHR) | |
|---|---|---|
| Market cap | $20.5B | $23.0B |
| Revenue (latest FY) | $8.26M | $3.18B |
| Net income (latest FY) | $-299.77M | $1.33B |
| Revenue growth (5y CAGR) | -19.1% | 16.5% |
| Net margin | -3629.2% | 41.9% |
| Return on equity | -6.6% | 18.8% |
| P/E ratio | — | 20.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 8 |
| Positive free cash flow | No | Yes |
See the full ROIV vs UTHR breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ROIV's full financials → Open UTHR's full financials →More comparisons
Frequently asked questions
Which is bigger, ROIV or UTHR?
United Therapeutics Corporation is larger by market capitalization — $23.0B versus $20.5B.
Which grows faster, ROIV or UTHR?
Over the last five fiscal years, United Therapeutics Corporation grew revenue faster — 16.5%/yr versus -19.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.